Evidence map›Paper›PMID 36900218›Full record

ArticleCancers2023

The CXCL10/CXCR3 Pathway Contributes to the Synergy of Thermal Ablation and PD-1 Blockade Therapy against Tumors.

Wenlu Xiao, Hao Huang, Panpan Zheng, Yingting Liu, Yaping Chen, Junjun Chen, Xiao Zheng, Lujun Chen, Jingting Jiang

Full text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. [Progress in the Immune Mechanism of Microwave Ablation Therapy for Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenlu XiaoDepartment of Tumor Biological Treatment, Jiangsu Engineering Research Center for Tumor Immunotherapy, Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Hao HuangDepartment of Tumor Biological Treatment, Jiangsu Engineering Research Center for Tumor Immunotherapy, Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Panpan ZhengDepartment of Tumor Biological Treatment, Jiangsu Engineering Research Center for Tumor Immunotherapy, Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Yingting LiuDepartment of Tumor Biological Treatment, Jiangsu Engineering Research Center for Tumor Immunotherapy, Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Yaping ChenDepartment of Tumor Biological Treatment, Jiangsu Engineering Research Center for Tumor Immunotherapy, Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Junjun ChenDepartment of Tumor Biological Treatment, Jiangsu Engineering Research Center for Tumor Immunotherapy, Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Xiao ZhengDepartment of Tumor Biological Treatment, Jiangsu Engineering Research Center for Tumor Immunotherapy, Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Lujun ChenDepartment of Tumor Biological Treatment, Jiangsu Engineering Research Center for Tumor Immunotherapy, Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Jingting JiangDepartment of Tumor Biological Treatment, Jiangsu Engineering Research Center for Tumor Immunotherapy, Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.

Funding

Changzhou International Cooperation Project CZ2021005China Postdoctoral Science Foundation 2021M700543, 2021M700547High-Level Talents Project of Jiangsu Commission of Health LGY2020034National Natural Science Foundation of China 81972869, 82172689 and 81902386the Applied Basic Research Foundation of Changzhou CJ20210089the Key R&D Project of Changzhou CE20215030the Key R&D Project of Jiangsu Province BE2022721 and BE2022719the Natural Science Foundation of Jiangsu Province BK20211065the open fund of state key laboratory of Pharmaceutical Biotechnology, Nanjing University, China No. KF202203
6 · The paper itself

Abstract

As a practical local therapeutic approach to destroy tumor tissue, thermal ablation can activate tumor-specific T cells via enhancing tumor antigen presentation to the immune system. In the present study, we investigated changes in infiltrating immune cells in tumor tissues from the non-radiofrequency ablation (RFA) side by analyzing single-cell RNA sequencing (scRNA-seq) data of tumor-bearing mice compared with control tumors. We showed that ablation treatment could increase the proportion of CD8

Indexed as

cancer immunotherapyCXCL10microwave ablationthermal ablationtumor microenvironment

Identifiers

PMID36900218
PMCPMC10000434

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read20
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.